Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa

Earnings Call Insights: Co-Diagnostics (CODX) Q4 2024 Management View CEO Dwight Egan highlighted the development advancements of the Co-Dx PCR testing platform, including its low-cost, rapid, and easy-to-use features. The company withdrew its initial FDA 510(k) submission for the Co-Dx PCR COVID-19 test to address.